Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis
Phase 2
Completed
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: Silymarin 420 mgDrug: Silymarin 700 mgOther: Placebo
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Madaus Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00680407
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath